Filing Details

Accession Number:
0001209191-23-006886
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-02-03 16:33:55
Reporting Period:
2023-02-01
Accepted Time:
2023-02-03 16:33:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1404644 Neoleukin Therapeutics Inc. NLTX Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1914769 Michael Sean Smith C/O Neoleukin Therapeutics, Inc.
188 East Blaine Street, #450
Seattle WA 98102
Principal Accounting Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-02-01 12,500 $0.00 19,276 No 4 M Direct
Common Stock Disposition 2023-02-02 3,316 $0.60 15,960 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2023-02-01 12,500 $0.00 12,500 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
12,500 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  2. Represents the weighted average sale price. The lowest price at which shares were sold was $0.576 and the highest price at which shares were sold was $0.635. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth herein.
  3. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
  4. The RSUs will vest as to 1/2 of the total number of shares underlying the award on each of February 1, 2023 and February 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
  5. The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date.